CapsoVision Files S-1/A for Public Offering, Eyes Growth Capital
Ticker: CV · Form: S-1/A · Filed: Jun 13, 2025 · CIK: 1378325
| Field | Detail |
|---|---|
| Company | Capsovision, Inc (CV) |
| Form Type | S-1/A |
| Filed Date | Jun 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: S-1/A, IPO, Electromedical Devices, Emerging Growth Company, SEC Filing, Medical Technology, Capital Raise
Related Tickers: CV
TL;DR
**CapsoVision's S-1/A signals an imminent IPO, making it a speculative 'watch list' play for med-tech investors seeking early-stage growth.**
AI Summary
CapsoVision, Inc. filed an S-1/A on June 13, 2025, as Amendment No. 2 to its S-1 Registration Statement, indicating its intent to commence a proposed public sale of securities. The company, operating in the electromedical and electrotherapeutic apparatus sector, is headquartered at 18805 Cox Avenue, Suite 250, Saratoga, CA 95070. Kang-Huai (Johnny) Wang serves as President and CEO, overseeing operations for the non-accelerated filer. The filing specifies a delayed or continuous offering pursuant to Rule 415 under the Securities Act of 1933. While specific revenue and net income figures are not detailed in this amendment, the S-1/A signals a critical step towards a public offering, aiming to raise capital for future growth and operational expansion. Key risks will likely revolve around market acceptance of its medical devices and intense competition in the electromedical field. The strategic outlook is focused on leveraging the public market to fund product development and market penetration.
Why It Matters
This S-1/A filing is crucial for CapsoVision, Inc. as it moves closer to a public offering, potentially providing significant capital for research, development, and market expansion in the competitive electromedical device sector. For investors, it represents an opportunity to gain exposure to an emerging growth company in medical technology, though detailed financials are needed for a full assessment. Employees could see increased job security and growth opportunities as the company scales. Customers might benefit from accelerated product innovation and broader access to CapsoVision's electromedical and electrotherapeutic apparatus, intensifying competition with established players like Medtronic and Boston Scientific.
Risk Assessment
Risk Level: medium — The risk level is medium because CapsoVision is an 'emerging growth company' and a 'non-accelerated filer,' as indicated in the S-1/A, suggesting it may have limited operating history or financial resources compared to larger, more established public companies. The filing also indicates a 'delayed or continuous basis' offering, which can introduce uncertainty regarding the timing and pricing of the securities.
Analyst Insight
Investors should closely monitor subsequent amendments to CapsoVision's S-1/A for detailed financial statements, business strategy, and risk factors before making any investment decisions. Given its 'emerging growth company' status, a thorough due diligence on its product pipeline, market position, and competitive landscape is essential.
Executive Compensation
| Name | Title | Total Compensation |
|---|---|---|
| Kang-Huai (Johnny) Wang | President and Chief Executive Officer |
Key Numbers
- 333-287148 — Registration No. (SEC registration number for the S-1 filing)
- 2025-06-13 — Filing Date (Date S-1/A was filed with the SEC)
- 3845 — SIC Code (Standard Industrial Classification for Electromedical & Electrotherapeutic Apparatus)
- 18805 Cox Avenue, Suite 250, Saratoga, CA 95070 — Business Address (Principal executive offices of CapsoVision, Inc.)
- +1-408-624-1488 — Business Phone (Telephone number for CapsoVision, Inc.)
Key Players & Entities
- CapsoVision, Inc. (company) — Registrant filing S-1/A
- Kang-Huai (Johnny) Wang (person) — President and Chief Executive Officer of CapsoVision, Inc.
- O'Melveny & Myers LLP (company) — Legal counsel for CapsoVision, Inc.
- Ellenoff Grossman & Schole LLP (company) — Legal counsel for CapsoVision, Inc.
- Portia Ku, Esq. (person) — Legal counsel from O'Melveny & Myers LLP
- Kurt Berney, Esq. (person) — Legal counsel from O'Melveny & Myers LLP
- Richard I. Anslow (person) — Legal counsel from Ellenoff Grossman & Schole LLP
- Jonathan Deblinger (person) — Legal counsel from Ellenoff Grossman & Schole LLP
- Joseph A. Smith (person) — Legal counsel from Ellenoff Grossman & Schole LLP
- Securities and Exchange Commission (regulator) — Regulatory body overseeing the S-1/A filing
FAQ
What is the purpose of CapsoVision, Inc.'s S-1/A filing?
CapsoVision, Inc.'s S-1/A filing, Amendment No. 2 to its S-1 Registration Statement, indicates its intent to commence a proposed public sale of securities as soon as practicable after the effective date. This is a crucial step towards becoming a publicly traded company and raising capital.
Who is the CEO of CapsoVision, Inc.?
Kang-Huai (Johnny) Wang is the President and Chief Executive Officer of CapsoVision, Inc. His contact information is listed as 18805 Cox Avenue, Suite 250, Saratoga, CA 95070, with a phone number of +1-408-624-1488.
What industry does CapsoVision, Inc. operate in?
CapsoVision, Inc. operates in the Electromedical & Electrotherapeutic Apparatus industry, as indicated by its Standard Industrial Classification (SIC) Code 3845. This suggests the company develops and manufactures medical devices.
Is CapsoVision, Inc. considered an emerging growth company?
Yes, CapsoVision, Inc. has indicated in its S-1/A filing that it is an 'emerging growth company.' This designation provides certain scaled-back disclosure requirements and exemptions from various regulatory provisions.
What is the address of CapsoVision, Inc.'s principal executive offices?
The principal executive offices of CapsoVision, Inc. are located at 18805 Cox Avenue, Suite 250, Saratoga, CA 95070. This address is also listed for their agent for service.
Which law firms are representing CapsoVision, Inc. in this filing?
O'Melveny & Myers LLP and Ellenoff Grossman & Schole LLP are representing CapsoVision, Inc. in this S-1/A filing. Portia Ku, Esq. and Kurt Berney, Esq. are listed from O'Melveny & Myers LLP, while Richard I. Anslow, Jonathan Deblinger, and Joseph A. Smith are listed from Ellenoff Grossman & Schole LLP.
What is the SEC file number for CapsoVision, Inc.'s registration statement?
The SEC file number for CapsoVision, Inc.'s registration statement is 333-287148. This number identifies the specific filing with the Securities and Exchange Commission.
When was CapsoVision, Inc.'s S-1/A filed?
CapsoVision, Inc.'s S-1/A was filed with the Securities and Exchange Commission on June 13, 2025. This date marks the official submission of the amendment.
What does it mean that CapsoVision, Inc. is a 'non-accelerated filer'?
Being a 'non-accelerated filer' means CapsoVision, Inc. does not meet the thresholds for accelerated or large accelerated filers, typically due to a public float below $75 million. This status allows for extended deadlines for filing certain reports with the SEC.
Will CapsoVision, Inc.'s securities be offered on a delayed or continuous basis?
Yes, the S-1/A filing indicates that if any of the securities being registered are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, the corresponding box is checked. This suggests flexibility in the timing of the offering.
Industry Context
CapsoVision operates in the electromedical and electrotherapeutic apparatus sector, a field characterized by rapid technological advancements and significant R&D investment. The industry is highly competitive, with established players and emerging companies vying for market share through innovation and regulatory approvals.
Regulatory Implications
As a medical device company, CapsoVision faces stringent regulatory oversight from bodies like the FDA. Compliance with manufacturing standards, clinical trial requirements, and post-market surveillance are critical. The S-1 filing itself is a regulatory process, requiring detailed disclosures about the business, financials, and risks.
What Investors Should Do
- Monitor subsequent S-1 filings for detailed financial statements and updated risk factors to assess the company's financial health and potential challenges.
- Research the competitive landscape within the electromedical and electrotherapeutic apparatus sector to understand CapsoVision's market position and growth potential.
- Evaluate the company's product pipeline and intellectual property strategy as disclosed in future filings to gauge its innovation capabilities.
Key Dates
- 2025-06-13: Filing of Amendment No. 2 to S-1 Registration Statement — Indicates the company is moving forward with its public offering plans, signaling a significant step towards accessing capital markets.
Glossary
- S-1/A
- An amendment to an S-1 Registration Statement, which is filed with the SEC by companies intending to offer securities to the public. (This document is the core filing detailing CapsoVision's intent to go public and the terms of the offering.)
- Rule 415
- A SEC rule that permits companies to register securities for a delayed or continuous offering, allowing them to sell securities over time as needed. (CapsoVision is utilizing this rule, indicating a flexible approach to capital raising rather than a single, immediate offering.)
- Non-accelerated filer
- A classification for public companies that do not meet the thresholds for accelerated or large accelerated filer status, typically based on public float. (This classification suggests CapsoVision is a smaller company in terms of market capitalization, which may influence reporting requirements and investor perception.)
- SIC Code 3845
- Standard Industrial Classification code for Electromedical & Electrotherapeutic Apparatus. (This code categorizes CapsoVision's business, placing it within a specific segment of the medical device industry.)
Year-Over-Year Comparison
As this is Amendment No. 2 to the initial S-1 filing, a direct comparison of key metrics like revenue growth or margin changes to a prior year's financial performance is not yet possible from this amendment alone. The focus of this filing is on updating the registration statement and signaling progress towards an offering, rather than presenting comparative financial results. New or updated risk factors may be introduced, reflecting evolving market conditions or company developments.
Filing Details
This Form S-1/A (Form S-1/A) was filed with the SEC on June 13, 2025 by Kang-Huai (Johnny) Wang regarding CapsoVision, Inc (CV).